The Latin America Fusion Biopsy Market was valued at $50 Million in 2024 and projected to reach to $66.5 Million by 2029, representing a compound annual growth rate of 5.9%. Latin America's fusion biopsy market is positioned for steady expansion as healthcare providers increasingly recognize the clinical value of image-guided diagnostic procedures.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America's fusion biopsy market is expanding at a CAGR of 5.9%, growing from $50.0 million in 2024 to $66.5 million by 2029, reflecting increasing adoption of advanced diagnostic technologies across the region.
Fusion biopsy systems are gaining significant traction in Latin American oncology and urology departments, where precision diagnostics are becoming critical for improved patient outcomes and treatment planning.
Latin America's healthcare sector is increasingly investing in advanced diagnostic infrastructure, with fusion biopsy technology becoming a priority for hospitals and diagnostic centers seeking to enhance clinical capabilities.
While Latin America shows solid growth at 5.9% CAGR, it trails the global fusion biopsy market growth rate of 7.1%, indicating untapped potential for market expansion and technology penetration in the region.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | TRANSPERINEAL (Route Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 7.1% from 2024 to 2029 |
| Largest Segment | PROSTATE CANCER (Application) |
| Market Size Base Year (Billions) | ~USD 0.65 (2024) |
| Revenue Forecast (Billions) | ~USD 0.91 (2029) |
| Segments Covered | Route Type, Application, Product, End User |
4 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|
The fusion biopsy market in Latin America was valued at $50.0 million in 2024 and is projected to grow to $66.5 million by 2029.
Latin America's fusion biopsy market is growing at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2029.
Brazil, Mexico, and Argentina are the primary markets driving fusion biopsy adoption in Latin America due to their advanced healthcare infrastructure and rising diagnostic demand.
Growth in Latin America is driven by increasing cancer incidence, healthcare modernization, improved reimbursement policies, and rising clinician adoption of precision diagnostic technologies.
The fusion biopsy market in Latin America is forecasted to reach $66.5 million by 2029, representing a $16.5 million increase from 2024 levels.
To determine the current size of the fusion biopsy market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.
The four steps involved in estimating the market size are
Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (like D&B Hoovers, Bloomberg Business, and Factiva), white papers, certified publications, articles by well-known authors, annual reports, press releases, and investor presentations of companies.
In the primary research phase, a comprehensive approach was employed, involving the interviewing of several sources from both the supply and demand sides. The purpose of these interviews was to obtain the quantitative and qualitative information needed to put up this report. The main sources of information were industry experts from both core and related sectors, as well as preferred manufacturers, distributors, suppliers, pioneers in technology, and organizations involved in every aspect of this industry's value chain. A variety of primary respondents, including important industry stakeholders, subject-matter experts, C-level executives from crucial market companies, and industry advisers, were carefully questioned in-depth. The goal was to gather and validate important qualitative and quantitative insights and to conduct a thorough assessment of future possibilities.
A breakdown of the primary respondents is provided below:
Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION | |
|---|---|---|
| GE Healthcare | Business Manager | |
| Koninklijke Philips N.V. | Marketing Manger | |
| FUJIFILM Corporation | Consultant | |
All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the fusion biopsy market was also split into various segments and subsegments at the region and country level based on:
Both top-down and bottom-up approaches were used to estimate and validate the total size of fusion biopsy market.

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. By examining a number of variables and patterns from the supply and demand sides, the data was triangulated.
A fusion biopsy device is an advanced diagnostic tool that combines MRI and ultrasound imaging to create a detailed 3D visualization of the prostate. This device enables precise identification of abnormal tissue areas, enhancing the accuracy of biopsy procedures by guiding the needle directly to the targeted regions.
Full forecast, segment splits, and company analysis for all Fusion Biopsy Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report